NCT02735876View on ClinicalTrials.gov

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2020

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

acalabrutinib

DRUG

ibrutinib

DRUG

rituximab

Sponsors

Lead Sponsor

Acerta Pharma BV

All Listed Sponsors

lead

Acerta Pharma BV

INDUSTRY

NCT02735876 - A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter